BIONDVAX PHARMACEUTICALS-ADR(NASDAQ:BVXV) stock News

BVXV Latest News, Press Relases and Analysis

All

Press Releases

2 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

2 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

2 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Reports Second Quarter Financial Results and Provides Business Update

2 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Reports Second Quarter Financial Results and Provides Business Update

3 years ago - By: Benzinga - Mentions: MTNB GNPX LEGN CNSP ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax to Present at BIO-Europe Spring

2 years ago - By: Seeking Alpha

Nasdaq grants BiondVax extension to regain compliance with listing rules (NASDAQ:BVXV)

2 years ago - By: BiondVax Pharmaceuticals Ltd.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

2 years ago - By: BiondVax Pharmaceuticals Ltd.

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

2 years ago - By: Benzinga - Mentions: GNLN PSTV IRIX ITRG ...

Stocks That Hit 52-Week Lows On Tuesday

2 years ago - By: Seeking Alpha

BiondVax stock +6% on license agreement to develop antibodies (NASDAQ:BVXV)

2 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax Presenting at BIO CEO & Investor Conference

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BiondVax CEO Issues Letter to Shareholders

3 years ago - By: BiondVax Pharmaceuticals Ltd.

BIONDVAX PHARMACEUTICALS-ADR (BVXV) Stock News

BVXV Latest News, Press Relases and Analysis

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

BiondVax Reports Second Quarter Financial Results and Provides Business Update

BiondVax Reports Second Quarter Financial Results and Provides Business Update

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

BiondVax to Present at BIO-Europe Spring

Nasdaq grants BiondVax extension to regain compliance with listing rules (NASDAQ:BVXV)

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules

Stocks That Hit 52-Week Lows On Tuesday

BiondVax stock +6% on license agreement to develop antibodies (NASDAQ:BVXV)

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

BiondVax Presenting at BIO CEO & Investor Conference

BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study

BiondVax’s Innovative Inhaled COVID-19 Therapy Virtually Eliminated SARS-COV-2 Virus in Preclinical In Vivo Study

BiondVax CEO Issues Letter to Shareholders

BiondVax Announces Closing of $8 Million Underwritten Public Offering